Sanofi
Q1 2022 Earnings Call
Apr 28, 2022, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Eva Schaefer-Jansen
Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi's 2022 first quarter results, followed by a Q&A session. As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to slide thre.
I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors. With that, please advance to slide four. Our speakers on the call today are Paul Hudson, chief executive officer, and John Reed, global head of R&D the global business unit heads, Bill Sibold, Thomas Triomphe, Olivier Charmeil and Julie Van Ongevalle and Jean-Baptiste de Chatillon, chief financial officer.
For the Q&A, you have two options to participate. Option one, click the raise hand icon at the bottom of your screen. Or option two, submit your questions by clicking the Q&A icon at the bottom of the screen. With that, I'd like to turn the call over to Paul.
Paul Hudson -- Chief Executive Officer
Well, thank you, Eva. Great introduction. And thanks to everyone for joining our call today. Delighted to be here and together with the members of the executive team to take you through the updates on our business and our financial performance.
Let's start with Q1 sales view. Well, we're truly excited about the outstanding results in the first quarter. The strong performance of our businesses exceeded market expectations with 8.6% growth on the top line and EPS up 16.1%. Our specialty care business continues to grow at a remarkable pace.
Dupixent posted high double-digit growth in the U.S. and strong ex U.S. sales now annualizing close to EUR 2 billion. We have once again accelerated our critical milestones with several new indications submitted in both the U.S.
and EU in pursuit of our greater than EUR 13 billion sales ambition for Dupixent. Vaccines reported good business momentum with strong growth in PPH and a further recovery in sales of travel and endemic vaccines. In general medicines, our play-to-win strategy continues to pay off, divesting non-core products and investing in transplant and other selected assets resulted in another quarter of growth for our core assets. Likewise, the consumer health business is executing on the strategy outlined at our capital markets day on February 5 of last year.